Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04635735 · OUTCOME

Phase I: Maximum Tolerated Dose of Ipilimumab

Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma · Source last updated 2023-03-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
1 year

What was measured

A maximum of 12 patients will be accrued and DLTs will be assessed in these patients. If any DLT is observed in more than one of the six patient cohort, a lower dose of ipilimumab will be evaluated in a new six patient cohort.

Analysis population: Data were not collected

Groups in this outcome

Ipilimumab After Stem Cell Transplantation

The patient will be admitted to a single room on the Adult Transplantation Service and allogeneic CD34-selected PBSC or marrow transplantation performed as per MSKCC adult BMT guidelines. Patients will be evaluated at approximately day 100 (±2 weeks) after allo-HSCT. Ipilimumab: Ipilimumab 3 mg/kg every 3 weeks for 4 doses.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Ipilimumab After Stem Cell Transplantation0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
A maximum of 12 patients will be accrued and DLTs will be assessed in these patients. If any DLT is observed in more than one of the six patient cohort, a lower dose of ipilimumab will be evaluated in a new six patient cohort.
groups
  1. description
    The patient will be admitted to a single room on the Adult Transplantation Service and allogeneic CD34-selected PBSC or marrow transplantation performed as per MSKCC adult BMT guidelines. Patients will be evaluated at approximately day 100 (±2 weeks) after allo-HSCT. Ipilimumab: Ipilimumab 3 mg/kg every 3 weeks for 4 doses.
    id
    OG000
    title
    Ipilimumab After Stem Cell Transplantation
population Description
Data were not collected
reporting Status
POSTED
time Frame
1 year
title
Phase I: Maximum Tolerated Dose of Ipilimumab
type
PRIMARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice